Live
FierceBiotechAlto halts work on PDE4 inhibitor after phase 2 schizophrenia failureFierceBiotechImmunovant’s FcRn inhibitor flunks phase 3 eye disease trials, validating biotech’s waning interestEndpoints NewsAlto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 missEndpoints NewsEli Lilly's chief technology officer retires after 35 years; Astellas strategy exec resignsEndpoints NewsImmunovant's FcRn drug fails in a pair of Phase 3 trials in thyroid eye diseaseAgilentAgilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader - BioSpaceLonza NewsImmuneOncia Therapeutics and Lonza collaborate to manufacture Danburstotug - Manufacturing ChemistThermo FisherCompagnie Lombard Odier SCmA Buys 5,895 Shares of Thermo Fisher Scientific Inc. $TMO - marketbeat.comAgilentAgilent expands India’s scientific ecosystem with new customer experience centre in Mumbai - Pharmabiz.comIlluminaIs It Time To Reassess Illumina (ILMN) After Its Recent Share Price Volatility? - simplywall.stFierceBiotechGilead cancels midstage HIV trial as FDA’s clinical hold remains intactEndpoints NewsGilead ends a Phase 2/3 trial of long-acting HIV pills
FierceBiotech Apr 2, 2026

Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure

Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure

Original
Body unavailable. Use the original source.

Directory

59 All